ProShare Advisors
STOK icon

ProShare Advisors’s Stoke Therapeutics STOK Stock Holding History

ProShare Advisors’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$314K Sell
9,654
-1,067
-10% -$35K ﹤0.01% 1309
2025
Q4 		$340K Buy
10,721
+1,099
+11% +$33K ﹤0.01% 1378
2025
Q3 		$226K Sell
9,622
-822
-8% -$14.1K ﹤0.01% 1633
2025
Q2 		$119K Buy
10,444
+280
+3% +$2.66K ﹤0.01% 1847
2025
Q1 		$67.6K Sell
10,164
-2,462
-19% -$23K ﹤0.01% 1912
2024
Q4 		$139K Buy
+12,626
New +$155K ﹤0.01% 1993
2022
Q1 		– Sell
-9,346
Closed -$224K – 2296
2021
Q4 		$224K Sell
9,346
-948
-9% -$22.6K ﹤0.01% 1960
2021
Q3 		$262K Sell
10,294
-1,255
-11% -$35K ﹤0.01% 1642
2021
Q2 		$389K Buy
11,549
+2,910
+34% +$103K ﹤0.01% 1713
2021
Q1 		$336K Buy
8,639
+300
+4% +$17.1K ﹤0.01% 1729
2020
Q4 		$516K Buy
8,339
+1,482
+22% +$67.9K ﹤0.01% 1257
2020
Q3 		$230K Buy
+6,857
New +$196K ﹤0.01% 1339
2020
Q1 		– Sell
-8,317
Closed -$236K – 1538
2019
Q4 		$236K Buy
+8,317
New +$209K ﹤0.01% 1486

Other funds holding STOK

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

ProShare Advisors's STOK Position: Q1 2026 in Review

ProShare Advisors reduced its Stoke Therapeutics (STOK) stake by 10% in Q1 2026, selling an estimated $35K and leaving 9,654 shares worth $314K. The position accounts for ﹤0.01% of the portfolio, ranked #1309.

ProShare Advisors first reported a position in STOK in Q4 2019 and has held it in 13 quarters since. The position peaked at $516K in Q4 2020. 196 funds tracked by Wall St. Rank hold STOK as of Q1 2026.

  • ProShare Advisors held 9,654 shares of Stoke Therapeutics worth $314K as of Q1 2026.
  • ProShare Advisors sold 1,067 Stoke Therapeutics shares in Q1 2026, an estimated $35K.
  • Stoke Therapeutics made up ﹤0.01% of ProShare Advisors's portfolio in Q1 2026, its #1309 holding.
  • ProShare Advisors first reported a position in Stoke Therapeutics in Q4 2019 and has held it in 13 quarters since.
  • ProShare Advisors's Stoke Therapeutics position peaked at $516K in Q4 2020.
  • 196 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2026.

Based on ProShare Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.